<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381547</url>
  </required_header>
  <id_info>
    <org_study_id>17298</org_study_id>
    <secondary_id>J1L-AM-JZGF</secondary_id>
    <secondary_id>AM0010-802</secondary_id>
    <nct_id>NCT03381547</nct_id>
  </id_info>
  <brief_title>A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)</brief_title>
  <acronym>Willow 2</acronym>
  <official_title>An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARMO BioSciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of different dose levels and dose formulations of
      pegilodecakin in healthy adult participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, randomized, single dose, 3-way crossover study to evaluate the
      pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy
      adult participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Actual">February 11, 2018</completion_date>
  <primary_completion_date type="Actual">February 11, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, Cmax</measure>
    <time_frame>43 days</time_frame>
    <description>maximal plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, Tmax</measure>
    <time_frame>43 days</time_frame>
    <description>maximal concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, AUC</measure>
    <time_frame>43 days</time_frame>
    <description>area under the plasma concentration curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, CL/F</measure>
    <time_frame>43 days</time_frame>
    <description>clearance (CL/F).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>43 days</time_frame>
    <description>Incidence of adverse events, injection site reactions, clinically relevant changes in laboratory values, and vital signs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegilodecakin: Dose level depending on weight will be 0.8 mg or 1.6 mg, dose formulation 4 mg/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 4 mg/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 2 mg/mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegilodecakin</intervention_name>
    <description>Pegilodecakin Alone</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>LY3500518</other_name>
    <other_name>AM0010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between 18 and 55 years of age, inclusive

          2. Must have a body mass index (BMI) between 19 and 32 (kg/m2) at study Screening

          3. Must be HIV negative by HIV 1/0/2 testing

          4. Must be Hepatitis B (HBV) surface antigen negative

          5. Must be Hepatitis C (HCV) antibody negative

          6. Females must have a negative serum pregnancy test

          7. Females of childbearing potential must agree to utilize protocol recommended highly
             effective contraception methods from Screening throughout the duration of study dosing
             and for 30 days following the last dose of study drug.

          8. Must refrain from blood donation from 30 days prior to Day 0 through completion of the
             study and continuing for at least 30 days from date of last dose of study drug

        Exclusion Criteria:

          1. Pregnant or lactating subjects

          2. Have previously participated in an investigational trial involving administration of
             any investigational compound within 30 days prior to the study dosing

          3. Have poor venous access and are unable to donate blood

          4. Have been vaccinated within 90 days of study dosing

          5. Current alcohol or substance abuse judged by the Investigator to interfere with
             subject compliance

          6. Have history of significant drug sensitivity or drug allergy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

